255 related articles for article (PubMed ID: 29028854)
1. Clinical Insights and Emerging Strategies in Managing Cutaneous T-Cell Lymphoma.
Patrone CC; Geskin LJ
J Drugs Dermatol; 2017 May; 16(5):405-412. PubMed ID: 29028854
[TBL] [Abstract][Full Text] [Related]
2. Multidisciplinary Management of Mycosis Fungoides/Sézary Syndrome.
Berg S; Villasenor-Park J; Haun P; Kim EJ
Curr Hematol Malig Rep; 2017 Jun; 12(3):234-243. PubMed ID: 28540671
[TBL] [Abstract][Full Text] [Related]
3. Mycosis fungoides and Sézary syndrome: Australian clinical practice statement.
Bhabha FK; McCormack C; Wells J; Campbell BA; Newland K; Lade S; Buelens O; Joske D; Shortt J; Mapp S; Radeski D; Hertzberg M; Khot A; Van Der Weyden C; Khoo C; Hawkes E; Prince HM
Australas J Dermatol; 2021 Feb; 62(1):e8-e18. PubMed ID: 33368169
[TBL] [Abstract][Full Text] [Related]
4. Guidelines for phototherapy of mycosis fungoides and Sézary syndrome: A consensus statement of the United States Cutaneous Lymphoma Consortium.
Olsen EA; Hodak E; Anderson T; Carter JB; Henderson M; Cooper K; Lim HW
J Am Acad Dermatol; 2016 Jan; 74(1):27-58. PubMed ID: 26547257
[TBL] [Abstract][Full Text] [Related]
5. How we treat advanced stage cutaneous T-cell lymphoma - mycosis fungoides and Sézary syndrome.
Sethi TK; Montanari F; Foss F; Reddy N
Br J Haematol; 2021 Nov; 195(3):352-364. PubMed ID: 33987825
[TBL] [Abstract][Full Text] [Related]
6. Primary cutaneous T-cell lymphomas other than mycosis fungoides and Sézary syndrome. Part II: Prognosis and management.
Oh Y; Stoll JR; Moskowitz A; Pulitzer M; Horwitz S; Myskowski P; Noor SJ
J Am Acad Dermatol; 2021 Nov; 85(5):1093-1106. PubMed ID: 33945836
[TBL] [Abstract][Full Text] [Related]
7. Cutaneous T cell lymphoma: mycosis fungoides, Sézary syndrome, and other variants.
Edelson RL
J Am Acad Dermatol; 1980 Feb; 2(2):89-106. PubMed ID: 6988470
[TBL] [Abstract][Full Text] [Related]
8. Cutaneous T cell lymphoma-mycosis fungoides and Sezary syndrome: an update.
Parker SR; Bethaney JV
G Ital Dermatol Venereol; 2009 Aug; 144(4):467-85. PubMed ID: 19755952
[TBL] [Abstract][Full Text] [Related]
9. [Clinical characteristics of mycosis fungoides and Sézary syndrome].
Krc L; Dobesová J; Bucek M; Dusek J; Macák J; Galuszková D; Jurysek O
Vnitr Lek; 1997 May; 43(5):285-9. PubMed ID: 9601850
[TBL] [Abstract][Full Text] [Related]
10. Review of the treatment of mycosis fungoides and sézary syndrome: a stage-based approach.
Horwitz SM; Olsen EA; Duvic M; Porcu P; Kim YH
J Natl Compr Canc Netw; 2008 Apr; 6(4):436-42. PubMed ID: 18433609
[TBL] [Abstract][Full Text] [Related]
11. Lymphoma-associated hemophagocytic syndrome (LAHS) in advanced-stage mycosis fungoides/Sézary syndrome cutaneous T-cell lymphoma.
Blom A; Beylot-Barry M; D'Incan M; Laroche L
J Am Acad Dermatol; 2011 Aug; 65(2):404-410. PubMed ID: 21550694
[TBL] [Abstract][Full Text] [Related]
12. Primary cutaneous T-cell lymphoma (mycosis fungoides and Sézary syndrome): part I. Diagnosis: clinical and histopathologic features and new molecular and biologic markers.
Jawed SI; Myskowski PL; Horwitz S; Moskowitz A; Querfeld C
J Am Acad Dermatol; 2014 Feb; 70(2):205.e1-16; quiz 221-2. PubMed ID: 24438969
[TBL] [Abstract][Full Text] [Related]
13. Primary cutaneous T-cell lymphoma (mycosis fungoides and Sézary syndrome): part II. Prognosis, management, and future directions.
Jawed SI; Myskowski PL; Horwitz S; Moskowitz A; Querfeld C
J Am Acad Dermatol; 2014 Feb; 70(2):223.e1-17; quiz 240-2. PubMed ID: 24438970
[TBL] [Abstract][Full Text] [Related]
14. [Mycosis fungoides and Sézary syndrome : a systematic review].
André F; Guenova E; Blanchard G
Rev Med Suisse; 2022 Mar; 18(775):578-589. PubMed ID: 35353453
[TBL] [Abstract][Full Text] [Related]
15. A cutaneous lymphoma international prognostic index (CLIPi) for mycosis fungoides and Sezary syndrome.
Benton EC; Crichton S; Talpur R; Agar NS; Fields PA; Wedgeworth E; Mitchell TJ; Cox M; Ferreira S; Liu P; Robson A; Calonje E; Stefanato CM; Wilkins B; Scarisbrick J; Wain EM; Child F; Morris S; Duvic M; Whittaker SJ
Eur J Cancer; 2013 Sep; 49(13):2859-68. PubMed ID: 23735705
[TBL] [Abstract][Full Text] [Related]
16. [Item no 164: malignant lymphoma: cutaneous lymphoma].
CEDEF
Ann Dermatol Venereol; 2008 Nov; 135(11 Suppl):F160-2. PubMed ID: 18984207
[No Abstract] [Full Text] [Related]
17. Efficacy and tolerability of currently available therapies for the mycosis fungoides and Sezary syndrome variants of cutaneous T-cell lymphoma.
Whittaker SJ; Foss FM
Cancer Treat Rev; 2007 Apr; 33(2):146-60. PubMed ID: 17275192
[TBL] [Abstract][Full Text] [Related]
18. Prognostic factors and prediction of prognosis by the CTCL Severity Index in mycosis fungoides and Sézary syndrome.
Klemke CD; Mansmann U; Poenitz N; Dippel E; Goerdt S
Br J Dermatol; 2005 Jul; 153(1):118-24. PubMed ID: 16029336
[TBL] [Abstract][Full Text] [Related]
19. [Current therapeutic options in Mycosis fungoides and Sézary syndrome].
Albrecht JD; Nicolay JP
Hautarzt; 2022 Jan; 73(1):75-85. PubMed ID: 34988613
[TBL] [Abstract][Full Text] [Related]
20. New options in diagnosis and management of mycosis fungoides and Sézary syndrome.
Enke CA
Oncology (Williston Park); 2010 May; 24(6):507-8. PubMed ID: 20568591
[No Abstract] [Full Text] [Related]
[Next] [New Search]